Velicept Therapeutics Overview

  • Founded
  • 2015
Founded
  • Status
  • Private
  • Employees
  • 10
Employees
  • Latest Deal Type
  • Debt - PPP
  • Investors
  • 7

Velicept Therapeutics General Information

Description

Developer of drugs designed to transform the treatment of overactive bladder. The company's drugs are made using a novel compound which is a highly differentiated and selective compound that relaxes the bladder smooth muscle by stimulating beta 3-adrenoceptors, enabling physicians to have drugs with the potential to improve patients' lives.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • 640 Lee Road
  • Suite 119
  • Wayne, PA 19087
  • United States
+1 (484) 000-0000

Velicept Therapeutics Timeline

2018201920202021
Financing RoundFinancing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Velicept Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Debt - PPP 15-Apr-2020 0000 Completed Generating Revenue
4. Early Stage VC (Series B) 19-Nov-2019 00.00 0000 000.00 Completed Generating Revenue
3. Debt - General 01-Oct-2018 0000 000.00 Completed Generating Revenue
2. Early Stage VC (Series B) 16-Jul-2018 $15.5M $42.8M 000.00 Completed Generating Revenue
1. Early Stage VC (Series B) 01-May-2017 $27.3M $27.3M 000.00 Completed Startup
To view Velicept Therapeutics’s complete valuation and funding history, request access »

Velicept Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B 00,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Series A 0,000,000 00.000000 00.00
To view Velicept Therapeutics’s complete cap table history, request access »

Velicept Therapeutics Patents

Velicept Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20170348263-A1 Compositions and methods of using modified release solabegron for lower urinary tract symptoms Abandoned 03-Jun-2016 0000000000 0
US-20170348288-A1 Dosing regimens for beta-3 adrenoceptor agonists and anti-muscarinic agents for the treatment and prevention of lower urinary tract symptoms and overactive bladder Abandoned 03-Jun-2016 0000000000
EP-3463307-A1 Compositions and methods of using modified release solabegron for lower urinary tract symptoms Withdrawn 03-Jun-2016 0000000000
EP-3463307-A4 Compositions and methods of using modified release solabegron for lower urinary tract symptoms Withdrawn 03-Jun-2016 0000000000 0
EP-3463312-A1 Dosing regimens for beta-3 adrenoceptor agonists and anti-muscarinic agents for the treatment and prevention of lower urinary tract symptoms and overactive bladder Withdrawn 03-Jun-2016 A61K31/426

Velicept Therapeutics Executive Team (5)

Name Title Board Seat Contact Info
James Walker Chief Executive Officer, President & Chairman
Douglas Gessl Chief Financial Officer
Eliot Ohlstein Ph.D Chief Scientific Officer
Clarence Young MD Chief Medical Officer
You’re viewing 4 of 5 executive team members. Get the full list »

Velicept Therapeutics Board Members (9)

Name Representing Role Since
Cory Freedland Ph.D Samsara BioCapital Board Member 000 0000
James Walker Velicept Therapeutics Chief Executive Officer, President & Chairman 000 0000
Jill Mast Velicept Therapeutics Board Member 000 0000
Oren Isacoff MD Longitude Capital Board Observer 000 0000
You’re viewing 4 of 9 board members. Get the full list »

Velicept Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Velicept Therapeutics Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
CDK Associates Other 000 0000 000000 0
Samsara BioCapital Venture Capital Minority 000 0000 000000 0
Becker Ventures Venture Capital Minority 000 0000 000000 0
CAM Capital Asset Manager Minority 000 0000 000000 0
Fountain Healthcare Partners Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 7 investors. Get the full list »

Velicept Therapeutics Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
0000000 0000000000 15-Sep-2015 000000000000000000 Drug Discovery 0000000 0000000
To view Velicept Therapeutics’s complete acquisitions history, request access »